about
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosisKinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin.Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.Antimicrobial susceptibility testing of Chlamydia trachomatis using a reverse transcriptase PCR-based methodComparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.Accumulation of norfloxacin by Bacteroides fragilis.Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Moxifloxacin modulates inflammation during murine pneumonia.Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosisIn vitro activities of newer quinolones against bacteroides group organisms.In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.Activity of and resistance to moxifloxacin in Staphylococcus aureus.A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humaIn vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones.Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infectionsA thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.The new fluoroquinolones: A critical reviewMoxifloxacin in the treatment of skin and skin structure infections.Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humansToward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencingEvaluation of Moxifloxacin-induced Biochemical Changes in MiceMoxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniaeIn vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cellsPharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administrationActivity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Penetration of moxifloxacin into peripheral compartments in humans.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.
P2860
Q28368317-230D49FE-A65C-4218-840C-0DC747FE2680Q28369466-0E5DE206-114B-435E-9DF4-F60782BE3CC4Q33644159-C1B27639-D4D4-49A5-BD0B-F8D88CEEFAFEQ33694143-3B16A3B1-2D67-46CC-8652-36A57E1CAC1DQ33977723-07AEB28F-4FAB-4341-A17C-B0A02F5C08F1Q33979988-BF7875BD-DDC5-4804-9A12-4C436CA48BBEQ33980437-B53E02D5-AA01-4EF4-8EB5-CCF95CFBBD99Q33980689-7502B146-67FB-422E-8412-62D06250111CQ33986123-510CE059-1E32-4E4E-96D7-BEF10EB9D320Q34108091-8F34CCC9-85CE-4F54-AFA7-11C635C43FADQ34143059-0112000B-4FF9-41CB-A487-D7B2F0C6D2D1Q34301520-8739B734-E793-4639-A623-86F6D3AD316BQ34885313-298A546B-DC72-4A40-896E-AA804F566958Q35076966-770E9123-59D2-4E86-B79E-6813B8391174Q35102717-D2EFC8BC-E2CB-46DC-87FF-D9B18F2CD98FQ35137233-271395EF-5FF4-4469-B7FE-16042EF36581Q35137355-3DFE5013-2088-4907-9643-2629EDED3D4EQ35137842-77FE17E2-4D0A-4660-91FE-DEC8C53D43F1Q35138287-87A49286-975E-4981-9803-934DAAAEC383Q35139557-F92BBAB6-3787-46E6-BC63-BDF90F55EF03Q35328383-35E1ACE7-844A-4F81-9C07-5B51FDC8C973Q35633293-937E0E77-18C2-49C3-B31A-2BE571324068Q35649595-A59FAA18-C3F5-4ACA-9381-796100FD7024Q35919259-368C5A86-6A1D-4431-B799-8809F6EFE539Q36047112-13424F51-367F-4F67-BBFE-7F072B0C3677Q36351477-F75DC4BF-7019-4EAE-B999-7545C15185F7Q36865298-13A625D1-10B8-4E52-8EFF-45AB845B2274Q36928663-C001B88D-C545-40F5-80C2-0FBD3CA5200BQ37071001-DDA921FD-96D7-41DE-B279-6C7D3FB59A13Q37865878-58F59605-1C33-470B-A7A8-4F71DC14A965Q37881176-A16C4824-D79E-4AF2-9137-D03005FA4551Q39456569-F8C14C1B-8531-40E5-A3BD-8152F6A49EC0Q39469480-EE2C417D-346A-401B-BC1F-D1E97CD9B689Q39471033-D37F4B26-C9B2-4EFA-8FD6-53F51888CEF3Q39471111-1856B96C-E647-416F-8311-FDA1A070B52DQ39471404-F9AD552B-CC1B-4806-8B07-E91AC1CF9C1EQ39471855-6193E7E5-1B22-4029-9A51-7AB094264EB9Q39477371-313F324C-6659-48A5-8E0D-C6552C82BE8DQ39478033-A8BC37AB-57B9-49ED-9F37-0D1EF8E71A70Q39478796-AAFC8F69-5C0A-498C-918A-73AF4E6CAF89
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
In vitro activity of BAY 12-8039, a new fluoroquinolone
@ast
In vitro activity of BAY 12-8039, a new fluoroquinolone
@en
In vitro activity of BAY 12-8039, a new fluoroquinolone
@nl
type
label
In vitro activity of BAY 12-8039, a new fluoroquinolone
@ast
In vitro activity of BAY 12-8039, a new fluoroquinolone
@en
In vitro activity of BAY 12-8039, a new fluoroquinolone
@nl
prefLabel
In vitro activity of BAY 12-8039, a new fluoroquinolone
@ast
In vitro activity of BAY 12-8039, a new fluoroquinolone
@en
In vitro activity of BAY 12-8039, a new fluoroquinolone
@nl
P2093
P2860
P1476
In vitro activity of BAY 12-8039, a new fluoroquinolone
@en
P2093
F J Boswell
J M Andrews
J M Woodcock
N P Brenwald
P2860
P407
P577
1997-01-01T00:00:00Z